著者

Fu-Sheng Fang Zhi-Bing Li Chun-Lin Li Hui Tian Jian Li Xiao-Ling Cheng

出版者

一般社団法人 日本内科学会

雑誌

Internal Medicine (ISSN:09182918)

巻号頁・発行日

vol.51, no.22, pp.3109-3113, 2012 (Released:2012-11-15)

参考文献数

17

被引用文献数

3 11

---

Objective To investigate the influence of glycemic variability on the HbA1c level in elderly male patients with type 2 diabetes (T2DM). Methods The 24-h glucose profiles were obtained using a continuous glucose monitoring system in 291 elderly male type 2 diabetic patients. The relationship between the glycemic variability and HbA1c level was assessed in these patients. Results The mean amplitude of glycemic excursions (MAGE) in patients with HbA1c ≥7.0% was significantly higher than in patients with HbA1c <7.0% (4.33±1.67 vs. 3.48±1.46 mmol/L, p<0.001). A simple (Pearson's) correlation analysis indicated that the MAGE was significantly correlated with the HbA1c (r=0.229, p<0.001). Compared with the lowest quartile, the highest quartile of the MAGE was associated with a significantly increased risk of having a HbA1c ≥7.0% after multiple adjustments (p for trend <0.001). Conclusion The glycemic variability had a significant influence on the HbA1c level in elderly male patients with T2DM. The present data suggests that patients with higher glycemic variability might have higher HbA1c levels.

著者

Yan Hao Yu-lin Yang Yong-chao Wang Jian Li

出版者

International Heart Journal Association

雑誌

International Heart Journal (ISSN:13492365)

巻号頁・発行日

pp.22-052, (Released:2022-07-14)

参考文献数

22

被引用文献数

8

---

Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors significantly reduce low-density lipoprotein cholesterol (LDL-C) and improve the prognosis of patients with acute coronary syndrome (ACS). However, the feasibility and safety of early application of PCSK9 inhibitors on the basis of statins combined with ezetimibe to strengthen lipid lowering in extremely high-risk coronary heart disease populations are still unknown.This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina. Adverse reactions included allergies, myalgia, poor blood glucose control, and liver damage.Within 1 month, the average level of LDL-C in the evolocumab group decreased from 3.54 to 0.57 mmol/L and that in the control group decreased from 3.52 to 1.26 mmol/L. The LDL-C compliance (< 1.0 mmol/L) rate was significantly increased in the evolocumab group compared with the control group (82.35% versus 22.06%, P < 0.01). The average level of lipoprotein (a) (Lp (a)) in the control group increased by 9.94 ± 51.93% from baseline after treatment, but evolocumab reduced the Lp (a) level (−38.84 ± 32.40%). Additionally, evolocumab further reduced the levels of apolipoprotein B/A1 (−70.56 ± 22.38% versus −51.29 ± 18.14%), cholesterol (−54.76 ± 18.10% versus −41.16 ± 18.14%), and apolipoprotein B (−66.47 ± 26.89% versus −46.78 ± 24.12%) compared with those in the control group, all P < 0.01. The blood lipid levels of both control and evolocumab groups stabilized after 1 month. During the 3-month follow-up, the incidence of MACEs after PCI was lower in the evolocumab group than in the control group (8.82% versus 24.59%, P = 0.015), and evolocumab combined with statins and ezetimibe did not increase the occurrence of adverse reactions (13.24% versus 11.48%, P = 0.762).In patients with extremely high-risk ACS with high levels of LDL-C, adding evolocumab to their treatment regimen as early as possible may enhance lipid lowering, increase the patient's LDL-C compliance rate in the short term, and improve cardiovascular prognosis but will not increase adverse reactions.

著者

Cunying Xu Yawei Liu Yixin Hua Jian Li Qibo Zhang

出版者

The Japan Institute of Metals and Materials

雑誌

MATERIALS TRANSACTIONS (ISSN:13459678)

巻号頁・発行日

vol.58, no.3, pp.377-382, 2017-03-01 (Released:2017-02-25)

参考文献数

24

被引用文献数

1 8

---

The electrochemical and chemical behaviors of titanium were examined in aluminum chloride-1-butyl-3-methylimidazolium chloride (AlCl3-BMIC) ionic liquid. The reduction of Ti(IV) in AlCl3-BMIC occurs in three consecutive steps: Ti(IV) → Ti(III) → Ti(II) → Ti, and Ti(III) ion can quickly react with Cl− anion to form sparingly soluble TiCl3. However, No elemental titanium can be obtained in either acidic or basic AlCl3-BMIC melt. Metal titanium can be oxidized to Ti(II) by Ti(IV) in AlCl3-BMIC melt. In addition, the anodic oxidation rate of titanium obviously increases in the presence of Ti(IV) and Ti(III) ions, suggesting that the anodic dissolution of titanium involves chemical dissolution. These results indicate that it is difficult to nucleate or stabilize pure titanium in ionic liquid, which makes pure titanium deposition quite difficult.

著者

JIAN LI

出版者

The Japan Landslide Society

雑誌

地すべり (ISSN:02852926)

巻号頁・発行日

vol.22, no.1, pp.15-17, 1985-06-15 (Released:2010-03-16)